From Wikipedia, the free encyclopedia
Apolizumab is a humanized monoclonal antibody that is being studied as a treatment for hematologic cancers.[1]
[edit] References
- ^ Bayes M, Rabasseda X, Prous J (2003). "Gateways to clinical trials.". Methods Find Exp Clin Pharmacol 25 (9): 747–71. PMID 14685303.
|
Humanized monoclonal antibodies ("-zu-") |
|
| "-tuzu-" (tumor) |
Alemtuzumab, Bevacizumab/ Ranibizumab, Bivatuzumab mertansine, Cantuzumab mertansine, Dacetuzumab, Etaracizumab, Etaratuzumab, Gemtuzumab ozogamicin, Inotuzumab ozogamicin, Labetuzumab, Lintuzumab, Matuzumab, Nimotuzumab, Pertuzumab, Sibrotuzumab, Sontuzumab, Tacatuzumab tetraxetan, Trastuzumab, Tucotuzumab celmoleukin
|
|
| "-lizu-" (immune system) |
Aselizumab, Atlizumab, Apolizumab, Cedelizumab, Certolizumab pegol, Daclizumab, Eculizumab, Efalizumab, Epratuzumab, Erlizumab, Fontolizumab, Ibalizumab, Lebrilizumab, Mepolizumab, Natalizumab, Ocrelizumab, Omalizumab, Pascolizumab, Pexelizumab, Reslizumab, Rovelizumab, Ruplizumab, Siplizumab, Talizumab, Teplizumab, Tocilizumab, Toralizumab, Visilizumab
|
|
| "-bazu-" (bacterial) |
|
|
| "-cizu-" (cardiovascular) |
|
|
| "-neuzu-" (nervous system) |
|
|
| "-toxazu-" (toxin as target) |
|
|
| "-vizu-" (viral infections) |
|
|
